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Functional profiling of single CRISPR/Cas9-edited
human long-term hematopoietic stem cells
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Joana Araújo1, Leonard D. Shultz2, Olga I. Gan1, John E. Dick 1,3* & Eric R. Lechman1*
In the human hematopoietic system, rare self-renewing multipotent long-term hematopoietic
stem cells (LT-HSCs) are responsible for the lifelong production of mature blood cells and are
the rational target for clinical regenerative therapies. However, the heterogeneity in the
hematopoietic stem cell compartment and variable outcomes of CRISPR/Cas9 editing make
functional interrogation of rare LT-HSCs challenging. Here, we report high efficiency LT-HSC
editing at single-cell resolution using electroporation of modified synthetic gRNAs and Cas9
protein. Targeted short isoform expression of the GATA1 transcription factor elicit distinct
differentiation and proliferation effects in single highly purified LT-HSC when analyzed with
functional in vitro differentiation and long-term repopulation xenotransplantation assays. Our
method represents a blueprint for systematic genetic analysis of complex tissue hierarchies
at single-cell resolution.
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The hematopoietic stem and progenitor cell (HSPC) com-partment is a functional continuum comprised of multiplestem and progenitor cell populations including abundant
committed progenitors such as common myeloid progenitors and
myelo–erythroid progenitors (MEPs), as well as rarer multipotent
stem cells including short-term hematopoietic stem cells (ST-
HSCs) and long-term hematopoietic stem cells (LT-HSCs)1,2
(Supplementary Fig. 1). LT-HSCs are the only population that
have the ability to permanently repopulate the entire hemato-
poietic system following transplantation2; they represent the key
target for blood-based regenerative therapies. Thus, LT-HSCs are
essential for therapeutic genome editing to correct acquired and
genetic hematopoietic disorders3,4. Furthermore, the pathogenesis
of hematological malignancies like acute myeloid leukemia
(AML) is associated with the presence of initiating mutations
acquired in LT-HSCs, which lead to their competitive expan-
sion5,6. Pre-leukaemic LT-HSCs are a source of clonal evolution
within blood malignancies and can act as a reservoir of relapse
after chemotherapy treatment7. Previous studies have shown the
feasibility of using genome editing techniques in human CD34+
cells to model hematological diseases, such as using CRISPR/Cas9
to induce myeloid neoplasia8 or using transcription activator-like
effector nucleases to induce chromosomal translocations to model
MLL-rearranged leukemia9. Thus, modeling and understanding
the genetic complexity and cellular heterogeneity seen in human
hematological malignancies using novel methodologies that allow
genome editing in highly purified single LT-HSCs and their
functional read-out are of great need3,4.
Recently several studies have demonstrated efficient gene
editing of bulk CD34+ populations that are enriched for human
HSPCs8,10–18. Highly efficient non-homologous end joining
(NHEJ)-mediated gene disruption of up to 80–90% efficiency has
been reported in CD34+ HSPCs12,13,15,17. In addition, homology-
directed repair (HDR)-mediated knock-ins, with or without
selectable fluorescent reporter genes, have been established with
an efficiency of up to 20% in CD34+ HSPCs10,11,13,14,16,18. Stable
integration of a fluorescent reporter using rAAV6 combined with
flow cytometry-based sorting enabled enrichment of CRISPR/
Cas9-edited HSPCs10,11,17. Because LT-HSCs represent only
0.1–1% of CD34+ populations, these studies did not address LT-
HSC targeting in the most direct manner. Previous studies have
reported long-term engraftment of up to 16 weeks following
xenotransplantation of CRISPR/Cas9 edited human CD34+
HSPCs10,16,18, suggesting that rare LT-HSCs within the CD34+
population can be gene edited. However, these studies utilized
considerable numbers of CD34+ HSPCs and lacked the resolu-
tion to functionally interrogate the differentiation and prolifera-
tion properties of individual LT-HSCs. In order to simplify LT-
HSC targeting within heterogeneous CD34+ HSPCs, we explored
the possibility of CRISPR/Cas9 editing in highly purified LT-
HSCs. This approach would enable direct functional character-
ization of LT-HSCs, rather than bulk populations. Here, we show
successful editing of highly purified LT-HSCs via CRISPR/Cas9-
mediated NHEJ or HDR and their subsequent functional inves-
tigation using single cell in vitro differentiation and near-clonal
xenotransplantation assays.
Results
CRISPR/Cas9-mediated GATA1 isoform expression in LT-
HSCs. As a proof of principle, we modeled GATA1 isoform
expression in LT-HSCs, ST-HSCs, and MEPs from neonatal cord
blood using CRISPR/Cas9. GATA1 encodes a DNA binding
protein with two zinc fingers and a transactivation domain that is
required for erythroid, megakaryocyte, mast cell, eosinophil, and
basophil differentiation19–21. Acquired and inherited GATA1
mutations contribute to hematological disorders such as Down
syndrome acute megakaryoblastic leukemia (AMKL), Diamond-
Blackfan anemia, transient myeloproliferative disorder and con-
genital dyserythropoietic anemias with thrombocytopenia22–27.
The GATA1 gene normally produces two protein isoforms as a
result of alternative mRNA splicing—the GATA1 full length
(GATA1-Long) and a truncated form (GATA1-Short). GATA1
isoform biology is particularly important for children with Down
syndrome and a subset of children born with Diamond-Blackfan
anemia. Children with Down syndrome have a 150-fold higher
risk of developing AMKL, which is characterized by an abnormal
proliferation of immature megakaryocytes28–30. Mutations in
exon 2, which lead to the exclusive expression of GATA1-Short,
are thought to be an essential driver of this disease. Previous work
has shown effects of GATA1-Short on megakaryocytic pro-
liferation, but these changes were only seen in fetal HSPCs and
not in neonatal or adult HSPCs, implying a developmental stage-
specific effect31,32. To verify this hypothesis, we decided to test
GATA1-Long versus GATA1-Short isoform expression in pur-
ified LT-HSCs, ST-HSCs, and MEPs from neonatal cord blood.
Overall, our experimental scheme employed flow cytometric
isolation of cord blood LT-HSCs for xenotransplantation and
isolation of LT-HSCs, ST-HSCs, and MEPs for single cell in vitro
differentiation assays (Supplementary Fig. 2). Sorted cells were
cultured for 48 h and electroporated with modified synthetic
gRNAs and Cas9 protein (Fig. 1a). During brief in vitro culturing,
LT-HSCs durably retain their immuno-phenotype with some
variability seen in ST-HSCs and MEP subsets. (Supplementary
Fig. 3). Because of the transient delivery of the ribonucleoprotein
complex and lack of a selectable marker, all CRISPR/Cas9-
mediated edits were subsequently genetically verified. To express
the GATA1-Short isoform, we used two gRNAs targeting the 5′
and 3′ flanking regions of exon 2, resulting in the NHEJ-mediated
dropout of the exon (Fig. 1b). By contrast, mutation of the
GATA1-Short alternative start site on exon 3 from ATG to CTC
via CRISPR/Cas9-mediated HDR led to the exclusive expression
of the GATA1-Long isoform (Fig. 1c). Importantly, expression of
both the GATA1-Short and -Long isoforms remained under the
regulatory control of the endogenous GATA1 promoter. Because
GATA1 is X-linked, all our studies utilized male cord blood
samples. As a control, we used two gRNAs targeting exon 1 of the
olfactory receptor OR2W5 that were designed with the CRoatan
algorithm33, resulting in a 150 bp dropout of the exon. After
electroporation, individual LT-HSCs, ST-HSCs, and MEPs were
deposited into single cell in vitro assays under erythro-myeloid
differentiation conditions[34] (Fig. 1a). After 16–17 days, each
single cell-derived colony was assessed by flow cytometry for
lineage output and the genotype of GATA1-Short or control
edited cells was determined by polymerase chain reaction (PCR),
whereas the genotype of GATA1-Long edited cells was assessed
by Sanger sequencing (Supplementary Fig. 4a–c). Moreover, LT-
HSCs that were CRISPR/Cas9 edited with GATA1-Short or
control gRNAs were transplanted into mice at a near-clonal level
in order to detect lineage and proliferation biases (Fig. 1a).
Single-cell differentiation of CRISPR/Cas9-edited LT-HSCs.
CRISPR/Cas9 editing efficiency in LT-HSCs, ST-HSCs, and MEPs
was high; the percentage of single cell-derived colonies with
homozygous deletion of OR2W5, GATA1-Short, and GATA1-
Long was 50–60%, 40%, and 20%, respectively (Fig. 2a and
Supplementary Fig 5a). Any control or GATA1-Short edited
single cell colony with only one gRNA cut and no exon dropout
was disregarded in the initial analysis. Although statistically
insignificant, CRISPR/Cas9-mediated HDR efficiencies were
lower in LT-HSCs than in ST-HSCs and MEPs (Fig. 2a). While
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electroporation by itself did not drastically affect the efficiency of
single cells to form colonies, LT-HSCs had slightly lower single
cell colony formation efficiencies compared to ST-HSCs and
MEPs (Fig. 2b). No off-target cleavage was detected at loci that
were similar in sequence to the gRNA target sequence by
amplicon Sanger sequencing (Supplementary Fig. 5b). Although
no whole genome sequencing was performed, the likelihood that
these results are due to off-target cleavage is extremely low. In
addition, karyotyping analysis revealed no structural abnormal-
ities after CRISPR/Cas9 editing in any of the conditions (Sup-
plementary Fig. 5c). Western assay of bulk CRISPR/Cas9-edited
MEPs cultured under erythro-myeloid conditions showed
enrichment of either the GATA1-Long or GATA1-Short isoform
(Fig. 2c, Supplementary Fig. 6a).
Culture of single LT-HSC, ST-HSC, and MEP under erythro-
myeloid differentiation conditions revealed a drastic shift towards
megakaryocytic lineage output upon exclusive expression of
GATA1-Short, with a twofold and fourfold increase in CD41+
megakaryocytic colonies compared to LT-HSCs expressing
control and GATA1-Long, respectively (Fig. 2d, e). Interestingly,
only GATA1-Short edited LT-HSCs produced bi-potent myelo-
megakaryocytic colonies. ST-HSCs showed even higher fold
increases toward megakaryocytic lineage output compared to LT-
HSCs. Whereas CRISPR/Cas9 control edited MEPs did not
possess any megakaryocytic differentiation capacity, GATA1-
Short edited MEPs were able to produce CD41+ megakaryocytes,
albeit with lower efficiency compared to LT-HSCs and ST-HSCs.
In order to mimic precise mutations at the 5′ splice junction of
exon 2 of patients with Down Syndrome associated leukemia26,
single-cell derived colonies were analyzed where only 1 gRNA
was utilized in order to target the 5′ splice site of exon 2
(Supplementary Fig. 6b–d). Similarly, there is an increase in the
number of megakaryocytic lineage positive colonies in
GATA1 splice junction edited LT-HSCs (M, Meg) and ST-
HSCs and MEPs (M, E, Meg) compared to control-edited
colonies. In addition to the engineering of CRISPR/Cas9-
mediated isoform re-arrangements, single gRNA mediated
knock-outs can also be utilized in our method; for example, they
can be used against STAG2 with single cell CRISPR/Cas9
efficiencies as high as 80–90% in LT-HSCs (Supplementary
Fig. 6e, f). In summary, purified LT-HSCs and more committed
stem and progenitor cells can be edited with high efficiency by
CRISPR/Cas9-mediated NHEJ and HDR, and the effects of gene
editing on differentiation can be read out reliably using single cell
in vitro assays.
Long-term xenotransplantation of CRISPR/Cas9-edited LT-
HSCs. Human LT-HSC can only be evaluated functionally using
the gold standard xenograft assay35. To investigate the functional
consequences of exclusive GATA1-Short expression in LT-HSCs
in vivo, we performed near-clonal xenotransplantation assays in
NSG mice. Limiting dilution analysis36 of CRISPR/Cas9 control-
edited LT-HSCs injected into NSG mice for 24 weeks revealed a
repopulating stem cell frequency of ~1/100 edited cells (Supple-
mentary Fig. 7a). To achieve near-clonal xenotransplantation, we
transplanted control- or GATA1-Short-edited LT-HSCs into
NSG mice at an equivalent dose of 100–150 cells/mouse and after
24 weeks analyzed bone marrow (BM) cells harvested from the
injected right femur (RF) and the left femur plus both tibias
(BM). Only mice with human CD45+ engraftment levels of >5%
in the RF and >90% CRISPR/Cas9 editing efficiency as deter-
mined by PCR and Sanger sequencing were included in our
analysis: 40% of control mice and 35% of mice transplanted with
a
Sort HSCs Electroporation
of RNPs
Single cell differentiation
(16–17 days)
Near-clonal xenotransplantation
(12/24 weeks)
0–103 103 104 105
0
–103
103
104
105
Flow cytometry
+ genotyping
Flow cytometry
+ genotyping
+
+
100 101 102 103 104 105
100 101 102 103 104 105
100
101
102
103
104
105
100
101
102
103
104
105
Cas9
ATG
1 2 3 4 5 6
GATA1
GATA1-Short
ATG
ATG
ATG
1
1 2 3 4 5 6
3 4 5 6
Cas9
gRNA1
gRNA2
GATA1-Long
b ATG
1 3 4 5 6
GATA1
GATA1-Long
ATG
ATG
ATG
gRNA1
Cas9
CTC
GATA1-Short
c
1 2
2 3 4 5 61
3 4 5 6
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GATA1-Short edited LT-HSCs fulfilled these criteria (Fig. 3a,
Supplementary Fig. 7b–f). To precisely determine the genotype of
the clonal progeny of injected LT-HSCs, secondary methylcellu-
lose colony formation assays from cells of the RF were carried
out. Analysis of CRISPR/Cas9 edits in individual colonies by
Sanger sequencing revealed clonal engraftment in 3 out of 5
GATA1-Short edited LT-HSCs injected mice, highlighting that
the xenotransplantations were indeed performed at near clonal
levels (Supplementary Fig. 7g). On average, human CD45+
engraftment in the RF was 40%, both in control and GATA1-
Short edited LT-HSCs injected mice (Fig. 3b). Interestingly,
GATA1-Short edited LT-HSCs generated grafts with twofold
higher percentage of human CD41+CD45− megakaryocytic
lineage derived cells in the RF compared to controls (Fig. 3c). In
addition, we observed an increase in the percentage of human
CD19+CD45+ B-lymphoid cells in the RF (Fig. 3d, Supplemen-
tary Fig. 8a–d). GATA1-Short edited LT-HSCs generated grafts
with higher absolute cell numbers, mainly due to increased
numbers of B-lymphoid lineage cells (Fig. 3e, Supplementary
Fig. 8e–i). The observed increase in megakaryocytic lineage
output in mice transplanted with GATA1-Short edited LT-HSCs
(Fig. 3f) confirms our single cell in vitro findings, and demon-
strates the feasibility of conducting near-clonal xenotransplanta-
tion assays using purified CRISPR/Cas9-edited LT-HSCs.
Normal human HSCs show a predominant B-lymphoid bias
upon long-term engraftment in NSG mice37. We therefore
repeated our xenotransplantation assays using c-kit-deficient
NSGW41 recipients, which support enhanced erythropoietic and
megakaryocytic lineage output38. Limiting dilution analysis of
CRISPR/Cas9-edited LT-HSCs in NSGW41 mice for 12 weeks
revealed a repopulating cell frequency of ~1/175 (Supplementary
Fig. 9a). Consequently, an equivalent dose of 200–250 control- or
GATA1-Short-edited LT-HSCs were transplanted into NSGW41
mice and human engraftment in the RF and BM was analyzed
after 12 weeks. Totally, 35% of mice transplanted with control
edited LT-HSCs and 30% of mice transplanted with GATA1-
Short edited LT-HSCs showed robust engraftment and successful
CRISPR/Cas9 editing (Fig. 4a, Supplementary Fig. 9b–d). Human
CD45+ engraftment was observed at comparable high levels as in
NSG mice (Fig. 4b). Strikingly, a threefold increase in CD41+
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megakaryocytic lineage output was observed in the RF and BM of
mice transplanted with GATA1-Short edited LT-HSCs (Fig. 4c).
No changes were seen in the percentage of B-lymphoid cells, but a
decrease in human GlyA+CD45− erythroid cells was detected in
mice transplanted with GATA1-Short edited LT-HSCs (Fig. 4d,
Supplementary Fig. 10a, b). Analysis of total cell numbers
revealed a similar pattern, including a threefold increase in the
number of megakaryocytic lineage derived cells and, at the same
time, a sixfold reduction in erythroid cell numbers (Fig. 4e,
Supplementary Fig. 10c–g). The cellular morphology of GlyA
+CD45− cells revealed more immature forms of erythroid cells
and fewer enucleated erythroblasts in the RF of GATA1-Short
edited LT-HSCs injected NSGW41 mice compared to control
(Supplementary Fig. 11a, b)39. No difference in morphology was
observed in CD41+ megakaryoblast-like cells in the BM of
GATA1-Short edited LT-HSCs injected NSGW41 mice compared
to control (Supplementary Fig. 11c). Only bulk CD41+ cells could
be sorted, regardless of CD45 staining, since sufficient numbers of
CD41+ CD45− megakaryocytes could not be detected after the
freeze/thaw cycle of stored BM. Furthermore, there were no
differences in B-lymphoid proliferation in grafts generated by
control- and GATA1-Short edited LT-HSCs in NSGW41 mice, in
contrast to our observations in NSG recipients, which was
possibly due to the reduced lymphoid bias observed in NSGW41
mice. In summary, xenotransplantation into NSGW41 mice
further augmented the megakaryocytic lineage output of GATA1-
Short edited LT-HSCs in vivo, with a concomitant decrease in
erythroid cells (Fig. 4f).
Discussion
We demonstrate that distinct numbers of isolated LT-HSCs as
well as more committed stem and progenitor cells can be edited
with high efficiency using CRISPR/Cas9. Conventional CRISPR/
Cas9 approaches on bulk CD34+ populations yield a mixed
population of edited and unedited cells, making functional
characterization difficult. Our approach, which requires retro-
spective verification of the CRISPR/Cas9 edits, permits the
functional interrogation of LT-HSCs at a single cell level. Alter-
native approaches utilize HDR-mediated stable integration of
selectable markers that allow prospective enrichment of CRISPR/
Cas9 edited cells upon expression of the fluorescent marker10,11.
The advantages of our method are that no exogenous sequences
are introduced into the genomic DNA and all regulatory pro-
cesses such as splicing and spatial control of promoters and
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enhancers are kept intact. In addition, we show for the first time
that GATA1-Short isoform expression in LT-HSCs under the
endogenous promoter leads to an increase in megakaryocytic
output; this was not previously observed in cord blood derived
bulk CD34+ HSPCs31. Aside from showing how a prototypical
transcription factor functions in regulating lineage fate in LT-
HSCs, this result is of great importance in modeling the normal
functions of the GATA1 transcription factor and the hematolo-
gical diseases where it is mutated.
Interestingly, our in vitro and in vivo data seem to closely phe-
nocopy several murine studies of GATA1 loss40, where mega-
karyocytes fail to undergo terminal differentiation and these
immature megakaryocytes expand dramatically in the BM and
spleen. Loss of GATA1 in mouse embryo-derived stem cells results
in a maturation arrest at the proerythroblast stage of definitive
erythroid precursors41 and ablation of GATA1 in adult mice results
in a maturation arrest at the proerythroblast stage42. However,
direct comparison of murine and human data is complicated by
the fact that human and mouse GATA1-Short are normally pro-
duced by divergent mechanisms, where human GATA1-Short is
generated through differential splicing and murine GATA1-Short is
produced by alternative translation of a single mRNA43. Indeed,
GATA1-Short mRNA transcripts have not been reported in murine
tissues43. Furthermore, although fetal hematopoiesis is perturbed in
mice with mutations conferring GATA1-Short expression, adult
mice display no obvious hematopoietic defects32.
Children born with Down syndrome have an increased risk of
developing AMKL, which is preceded by a pre-leukaemic syn-
drome termed transient leukemia that is characterized by high
numbers of abnormal megakaryoblasts in the circulation, spleen
and liver44. Nearly all cases of transient leukemia and Down
syndrome associated AMKL have N-terminal truncating GATA1
mutations (GATA1-Short) present at birth that become unde-
tectable after transient leukemia and AMKL remission28,45,46.
Notably, several transgenic mouse models of trisomy 21 and
GATA1-Short have been generated, yet none fully recapitulate the
hematological abnormalities and malignancies seen in human
trisomy 2132,47–49. Thus, the establishment of humanized in vivo
model systems suitable to study the pathogenesis of Down syn-
drome blood malignancy is imperative. While our work described
here represents an initial step, we foresee CRISPR/Cas9-mediated
GATA1-Short editing in primary trisomy 21 LT-HSCs in com-
bination with near clonal xenotransplantation as the most sui-
table approach to generate these models.
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Fig. 4 Functional interrogation of single CRISPR/Cas9-edited hematopoietic stem cells in NSGW41 mice. a Percentage of CRISPR/Cas9 edited LT-HSCs
injected NSGW41 mice with engraftment (>5% based on human CD45+ expression in RF) and high CRISPR/Cas9 knockout efficiency (>90% based on
PCR and Sanger sequencing) from each of three cohorts (n= 3 animal cohorts with independent cord blood pools). b Engraftment levels of control and
GATA1-short edited LT-HSCs injected NSGW41 mice based on human CD45+ expression in RF and BM. c Percentage of CD41+CD45−megakaryocytes of
control and GATA1-Short edited LT-HSCs injected NSGW41 mice in RF and BM (unpaired t test P < 0.001 for GATA1-Short versus control for both RF and
BM). d Percentage of GlyA+D45− erythroid cells in control and GATA1-Short edited LT-HSCs injected NSGW41 mice in RF and BM (unpaired t test P <
0.0005 for RF GATA1-Short versus RF control and unpaired t test P < 0.005 for BM GATA1-Short versus BM control). e Total cell numbers of different
lineages in control and GATA1-Short edited LT-HSCs injected NSGW41 mice in RF and BM (unpaired t test P < 0.005 for megakaryocytes GATA1-Short
versus control for both RF and BM and unpaired t test P < 0.005 for erythroid GATA1-Short versus control for both RF and BM). f Representative flow
cytometry plots of control and GATA1-Short edited LT-HSCs injected NSGW41 mice in RF showing CD41+CD45− megakaryocytes and GlyA+CD45−
erythroid cells. Error bars represent standard deviations
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Our observed phenotype of increased megakaryopoiesis due to
forced expression of GATA1-Short seems to be at odds with a
subset of Diamond Blackfan anemia patients, which is a genetic
disease that usually presents in infancy and is characterized by
low red blood cell counts. Most patients with Diamond Blackfan
anemia harbor mutations in genes coding for ribosomal subunits,
the most common being RPS19, that lead to a selective impaired
production of full-length GATA1 and GATA1-Short23,50,51.
Germline GATA1 mutations have also recently been described in
patients with Diamond Blackfan anemia22–24, which lead to
almost exclusive GATA1-Short expression, but no observed
increase in megakaryocytes. Thus, it is possible that in these
particular cases, germline GATA1 mutations severely constrained
fetal blood development inducing an unidentified compensatory
mechanism to allow for a more normalized megakaryocytic
development. This selective pressure is further supported by the
fact that mothers of children with Diamond Blackfan anemia
have increased numbers of miscarriages52.
In summary, our method opens up the possibility of studying
gene function relationships not only in LT-HSCs, but also in
other stem and progenitor cells to uncover cell type specific
phenotypes. We believe that the continuous improvement of
CRISPR/Cas9 editing efficiency, for example through chemically
modified gRNAs53–55 or different Cas9 variants56,57, will further
improve this approach. In the future, we envision that this
method could potentially be adapted for cellular therapies.
Methods
Cord blood lineage depletion. Human cord blood samples were obtained from
Trillium and William Osler hospitals with informed consent in accordance to
guidelines approved by University Health Network (UHN) Research Ethics Board.
Cord blood samples were processed 24–48 h after birth. Male samples were
exclusively utilized in this study because GATA1 and STAG2 are located on the X-
chromosome. This aided the CRISPR/Cas9 efficiency because of the need to edit
only one X-chromosome. Control OR2W5 is located on chromosome 1. Samples
were diluted 1:1 with phosphate-buffered saline (PBS) and mononuclear cells were
enriched using lymphocyte separation medium (Wisent, 305-010-CL). Subse-
quently, red blood cells were lysed using an ammonium chloride solution (Stem-
Cell Technologies, 07850). Then, lineage positive cells were depleted by negative
selection with the StemSep Human Hematopoietic Progenitor Cell Enrichment Kit
(StemCell Technologies, 14056) and Anti-Human CD41 TAC (StemCell Tech-
nologies, 14050) according to the manufacturer’s protocol. Lineage depleted cells
were stored in 50% PBS, 40% fetal bovine serum (FBS) (ThermoFisher, 12483-020)
and 10% DMSO (FisherScientific, D128-500) at −150 °C.
Cord blood sorting. Lineage depleted cells were thawed via slow dropwise addition of
X-VIVO 10 (Lonza, 04743Q) with 50% FBS (Sigma, 15A085) and DNaseI (200 µg/ml,
Roche, 10104159001). Cells were spun at 350×g for 10min at 4 °C and then resus-
pended in PBS+ 2.5% FBS. For all in vitro and in vivo experiments, the full stem and
progenitor hierarchy sort as described in Notta et al.34 was utilized in order to sort LT-
HSCs, ST-HSCs, and MEPs. Lineage depleted cells were resuspended in 100 μl per 1 ×
106 cells and stained in two subsequent rounds for 20min at room temperature each.
First, the following antibodies were used (volume per 1 × 106 cells, all from BD Bios-
ciences, unless stated otherwise): CD45RA FITC (5 μl, 555488, HI100), CD49f PE-Cy5
(3.5 μl, 551129, GoH3), CD10 BV421 (4 μl, 562902, HI10a), CD19 V450 (4 μl, 560353,
HIB19), and FLT3 CD135 biotin (12 μl, clone 4G8, custom conjugation). After washing
the cells, a second set of antibodies was used (volume per 1 × 106 cells, all from BD
Biosciences, unless stated otherwise): CD45 V500 (4 μl, 560777, HI30), CD34 APC-Cy7
(3 μl, clone 581, custom conjugation), CD38 PE-Cy7 (2.5 μl, 335825, HB7), CD90 APC
(4 μl, 559869, 5E10), CD7 A700 (10 μl, 561603, M-T701), and Streptavidin Conjugate
Qdot 605 (3 μl, ThermoFisher, Q10101MP). Cell sorting was performed on the FAC-
SAria III (BD Biosciences). LT-HSCs were sorted as CD45+CD34+CD38−CD45RA−
CD90+CD49f+, ST-HSCs as CD45+CD34+CD38−CD45RA−CD90−CD49f− and
MEPs as CD45+CD34+CD38+CD10/19−CD7−CD45RA−FLT3− (Supplementary
Figs. 1 and 2).
Pre-electroporation culture of sorted cells. Sorted LT-HSCs, ST-HSCs or MEPs
were cultured for 36–48 h in serum-free X-VIVO 10 (Lonza) media with 1%
Bovine Serum Albumin Fraction V (Roche, 10735086001), 1× L-Glutamine
(Thermo Fisher, 25030081), 1× Penicillin–Streptomycin (Thermo Fisher,
15140122) and the following cytokines (all from Miltenyi Biotec): FLT3L (100 ng/
mL), G-CSF (10 ng/mL), SCF (100 ng/mL), TPO (15 ng/mL), and IL-6 (10 ng/mL).
Cells were cultured in 96-well U-bottom plates (Corning, 351177).
gRNA and HDR template design. gRNAs for GATA1 Short and Long were
designed on Benchling (http://www.benchling.com). For GATA1 Short, gRNAs
sequences were considered that were flanking the 5′ and 3′ end of exon 2. Indi-
vidual gRNAs targeting the 5′ or 3′ end were individually tested for cleavage
efficiency and the best gRNA targeting each end was selected. Combined use of
both gRNAs enabled complete excision of exon 2 (Fig. 1b). For GATA1 Long,
gRNA sequences closest to the second ATG start codon were individually tested for
cleavage efficiency and the best gRNA was selected. The GATA1 Long HDR
template was designed with 60 bp homology ends at either side. For the template,
the ATG (Methionine) start codon was mutated to CTC (Leucine) and the PAM
sequence was mutated from GGG (Glycine) to GGC (Glycine) in order to avoid
repeated cutting by the gRNA (Fig. 1c). The control gRNAs, which target exon 1 of
the olfactory receptor OR2W5, were predicted by the CRoatan algrotihm33. The
STAG2 gRNA was predicted with the same algorithm.
gRNA and HDR template sequences:
Control gRNA-1: GACAACCAGGAGGACGCACT
Control gRNA-2: CTCCCGGTGTGGACGTCGCA
GATA1 Short gRNA-1: TGGAACGGGGAGATGCAGGA
GATA1 Short gRNA-2: CCACTCAATGGAGTTACCTG
GATA1 Long gRNA: CATTGCTCAACTGTATGGAG
GATA1 Long HDR template:
TCTTTCCTCCATCCCTACCTGCCCCCAACAGTCTTTCAGGTGTACCCA
TTGCTCAACTGTCTCGAGGGCATCCCAGGGGGCTCACCATATGCCGGCT
GGGCCTACGGCAAGACGGGGCTCTACCCTGCC
STAG2 gRNA: AATGGTCATCACCAACAGAA
CRISPR/Cas9 RNP electroporation. gRNAs were synthesized from IDT as Alt-R
CRISPR/Cas9 crRNA, which require annealing with Alt-R tracrRNA (IDT) to form
a functional gRNA duplex. The HDR template was synthesized from IDT as a
single-strand Ultramer. crRNAs and tracrRNAs were resuspended to 200 μM with
TE Buffer (IDT). Both RNA oligonucleotides were mixed 1:1 to a final con-
centration of 100 μM and annealed at 95 °C for 5 min in a thermocycler, then
cooled down to room temperature on the bench top. If using two gRNAs at the
same time, both crRNAs were annealed to the tracrRNA in a single tube. For each
reaction, 1.2 μl crRNA:tracrRNA, 1.7 μl Cas9 protein (IDT) and 2.1 μl PBS were
combined in a low-binding Eppendorf tube (Axygen, MCT-175-C-S) and incu-
bated for 15 min at room temperature. Subsequently, 1 μl of 100 μM electropora-
tion enhancer (IDT) was added. Pre-electroporation cultured cells were washed in
warm PBS and spun down at 350×g for 10 min at room temperature. Between 1 ×
104–5 × 104 cells per condition were resuspended in 20 μl of Buffer P3 (Lonza) per
reaction and quickly added to the Eppendorf tube containing the Cas9 gRNA RNP
complex. The mixture was briefly mixed by pipetting and then added to the
electroporation chamber (Lonza, V4XP3032). Cells were electroporated with the
program DZ-100 using the Lonza Nucleofector and, immediately afterwards, 180 μl
of pre-warmed X-VIVO 10 media (as described above) was added. Cells were
recovered overnight in the incubator before their use in in vivo or single cell
in vitro assays.
Setup of single cell in vitro assay. Single cell in vitro assays were performed
according to Notta et al.34 with slight modifications. Briefly, 3 days prior to the
single cell assay, Nunc 96-well flat bottom plates (Thermo Fisher, 167008) were
coated with 50 μl per well of 0.2% Gelatin (G1393, Sigma-Aldrich) using a mul-
tichannel pipette. The first and last column of each 96-well plate were not utilized
and instead filled with 150 μl PBS per well to support proper humidity within the
plate. After 1 h, the 0.2% Gelatin is removed and murine MS-5 stroma cells58 were
seeded at a density of 1500 cells per well in 100 μl H5100 media (StemCell
Technologies, 05150). One-day prior, the H5100 media was removed and replaced
with 100 μl of erythro-myeloid differentiation media. For this, StemPro-34 SFM
media (Thermo Fisher, 10639011) is used with the supplied supplement, 1× L-
Glutamine (Thermo Fisher, 25030081), 1× Penicillin–Streptomycin (Thermo
Fisher, 15140122), 10 μl Human LDL (StemCell Technologies, 02698) for every
50 ml media and the following cytokines (all from Miltenyi Biotec unless stated
otherwise): FLT3L (20 ng/mL), GM-CSF (20 ng/mL), SCF (100 ng/mL), TPO
(100 ng/mL), EPO (3 ng/mL, Eprex), IL-2 (10 ng/mL), IL-3 (10 ng/mL), IL-6
(50 ng/mL), IL-7 (20 ng/mL), and IL-11 (50 ng/mL). On the day of the experiment,
electroporated cells were stained with 1:2000 Sytox Blue (ThermoFisher, S34857) in
PBS+ 2.5% FBS and viable single cells were sorted and deposited into the MS-5
seeded 96 well plate using the FACSAria II (BD Biosciences). Single cells were
cultured for 16–17 days with an addition of 100 μl erythro-myeloid differentiation
media per well at day 8.
Flow cytometry of single cell in vitro assay. Wells with hematopoietic cell
content were marked 1 day prior and the total number of wells with colonies was
used to calculate CRISPR/Cas9 and single cell colony efficiencies. On the day of
analysis, 140 μl of media was removed from each well with a multichannel pipette
and the content was mixed well. Upon additional washing of the wells with PBS,
the content in each well was transferred to a 96-well filter plate (8027, Pall) in order
to remove stromal cells. For this, the filter plate was put on top of a 96-well
U-bottom plate (Corning, 351177) and centrifuged at 300×g for 7 min at room
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temperature. After the cells were pelleted at the bottom of the U-bottom plate, the
media was tossed by quickly inverting the U-bottom plate (~20 μl of liquid per well
remained). Then, 30 μl of PBS+ 2.5% FBS was added and mixed into each well
with a multichannel pipette and 25 μl (half) was transferred to a 96-well PCR plate
(Eppendorf, 951020362) for subsequent genomic DNA extraction (the PCR plate
was sealed and stored at -80C). After that, 25 μl of antibody mix in PBS+ 2.5% FBS
was added to each well, containing 25 μl of hematopoietic cells, and stained for 45
min at 4 °C. The following antibodies were used (all antibodies from BD Bios-
ciences, unless stated otherwise): CD45 APC (1:100, 560777, HI30), CD34 APC-
Cy7 (1:250, clone 581, custom conjugation), CD33 BV421 (1:50, Biolegend, 303416,
WM53), CD71 FITC (1:100, 347513, L01.1), CD41 PE-Cy5 (1:200, Beckman
Coulter, 6607116, P2) and GlyA PE (1:200, Beckman Coulter, IM2211U, KC16).
Finally, 150μl of PBS+ 2.5% FBS were added to each well with a multichannel
pipette and the cells were analyzed on the FACSCelesta with a high throughput
sampler (HTS, BD Biosciences). All flow cytometry quantification was performed
in a blinded manner. Generally, greater than ten cells were required to call a
positive lineage. Erythroid cells were defined as positive upon CD71 expression,
with or without expression of GlyA.
Genotyping of single cell in vitro assay. The PCR plates containing 25 μl of cells
per well were thawed and a modified protocol of the Agencourt GenFind V2
(Beckman Coulter, A41499) was utilized to isolate genomic DNA. Wells with cell
content were transferred to a new 96-well PCR plate (Eppendorf, 951020362) in
order to utilize multichannel pipetting for each future step. Totally, 25 μl of lysis
buffer and 1.2 μl of Proteinase K (Zymo Research, D3001220) were pipetted into
each well. After 30 min at room temperature, 50 μl of magnetic particles were
added. After 5 min, the PCR plate was placed on a magnetic stand (ThermoFisher,
AM10027) for 10 min. The supernatant was removed with a multichannel pipette
and the plate was taken off the magnet. Totally, 200 μl of wash buffer 1 were mixed
into each well and the PCR plate was put back onto the magnetic stand. After 10
min, the supernatant was removed and each well was washed with 125 μl of wash
buffer 2. Finally, after the last wash buffer was removed, the magnetic particles were
resuspended with 60 μl of TE buffer (IDT). The PCR plate was put back on the
magnetic stand and after 10 min, 57μl of eluted genomic DNA was removed and
put into a new PCR plate.
The CRISPR/Cas9 engineered genomic locus was amplified via PCR. For each
PCR reaction, 23 μl of eluted genomic DNA was mixed with 1 μl of forward and
reverse primer (10 μM) and 25 μl of AmpliTaq Gold 360 Master Mix
(ThermoFisher, 4398881). The PCR program was: 95 °C for 10 min, followed by 95
°C for 30 s, 56 °C for 30 s and 72 °C for 1 min (40 cycles) and then 72 °C for 7 min.
To identify colonies with the GATA1-Short genotype, 15μl of PCR product was run
on a 1.5% agarose gel (ThermoFisher, 16500500). Control gRNA colonies were
screened for homozygous deletion of OR2W5 (deletion within exon 1, 700 to 500
bp, (Supplementary Fig. 4a). Similarly, GATA1-Short colonies were screened for a
shift in the size of the PCR product (deletion of exon 2, 1000 to 550 bp,
Supplementary Fig. 4b). In order to identify colonies with the GATA1-Long
genotype, PCR products were column purified using the ZR-96 DNA Clean-up Kit
(Zymo Research, D4018) according to the manufacturer’s protocol. The purified
PCR product was Sanger sequenced using the reverse PCR primer and the
chromatograms were inspected to identify colonies that contained the alternative
start site mutation (Supplementary Fig. 4c). Finally, to identify STAG2 knock-out
colonies, PCR products were column purified and sent for Sanger sequencing using
the reverse PCR primer. Only colonies that showed a frame shift mutation were
considered positive (Supplementary Fig. 6f).
PCR primers:
Control (OR2W5) forward primer: 5′-TCGGCCTGGACTGGAGAAAA-3′
Control (OR2W5) reverse primer: 5′-GAGACCACTGTGAGGTGAGA-3′
GATA1-Short forward primer: 5′-CAGGAGAGAATGAGAAAAGAGTGGA-3′
GATA1-Short reverse primer: 5′-ATTTCCAAGTGGGTTTTTGAGGAT-3′
GATA1-Long forward primer: 5′-GCCACACTGAGAGGCAATACT-3′
GATA1-Long reverse primer: 5′-AAAAGTCAGGGCCCCCATAAG-3′
STAG2-forward primer: 5′-CCACAAAGAGGCTGTCACAGTT-3′
STAG2-reverse primer: 5′-CATGCAGCAGAAAATGAATCAAAAC-3′
Western assay. MEPs were sorted and CRISPR/Cas9 RNP electroporated as
described above. After electroporation, MEPs were cultured in erythro-myeloid
differentiation media (as described above for single cells in vitro assays) for 3 days.
1 × 105 cells were then lysed in RIPA buffer (ThermoFisher, 899000) containing
protease and phosphatase inhibitors (ThermoFisher, 78446). Subsequently, samples
were centrifuged at 12,000 g for 5 min at 4 °C and supernatants were utilized for
Western assay. Western assay was performed on the size-based Wes capillary
platform (ProteinSimple) using the 12–230 kDa capillary cartridge according to
manufacturer’s protocol. In order to determine the optimal antibody dilution, anti-
GATA-1 antibody (Cell Signaling D24E4) was titrated prior to use on a lysate from
CD34+ cord blood and 1:5 dilution was used in the samples.
Animal studies. All mouse experiments were approved by the University Health
Network (UHN) Animal Care Committee and we complied with all relevant ethical
regulations for animal testing and research. All mouse transplants were performed
with 8- to 12-week-old female NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) mice (JAX)
that were sublethally irradiated with 225 cGy, 24 h before transplantation, or with
8- to 12-week-old female NOD.Cg-PrkdcscidIl2rgtm1WjlKitem1Mvw/SzJ (NSGW41)
mice that were not irradiated. Sample size was chosen to give sufficient power for
calling significance with standard statistical tests. Intrafemoral injections were
performed as described in Mazurier et al59. For this, mice were anesthetized with
isoflurane and the right knee was secured in a bent position to drill a hole into the
RF with a 27 gauge needle. Then, 100–250 CRISPR/Cas9-edited LT-HSCs were
injected in 30 μl PBS using a 28 gauge ½ cc syringe (Becton Dickinson, 329461).
LT-HSC cell numbers are based on the number of flow cytometry sorted cells at
day 0. After 12 or 24 weeks, mice were sacrificed to obtain the RF and BM (left
femur and both tibias, BM). Bones were flushed in 1 mL PBS+ 2.5% FBS and cells
were centrifuged at 350×g for 10 min. Cells were resuspended in 500 μl of PBS+
2.5% FBS. Subsequently, cells from BM and RF were counted in ammonium
chloride (StemCell Technologies, 07850) using the Vicell XR (Beckman Coulter).
Totally, 25 μl of cells were used for flow cytometry analysis and another 25 μl were
frozen down for genomic DNA isolation in order to verify CRISPR/Cas9 edits
(same protocol as above for single cell in vitro assays).
Limiting dilution in vivo assays. For limiting dilution transplantation assays,
CRISPR/Cas9 control gRNA electroporated LT-HSCs were injected at defined
doses (equivalent to 25, 50, 100, and 200 LT-HSCs) into 8- to 12-week-old female
NSG or NSGW41 mice. LT-HSC cell numbers were based on the number of flow
cytometry sorted cells at day 0. LT-HSC frequency was estimated using the online
tool ELDA (http://bioinf.wehi.edu.au/software/elda/index.html)36.
Flow cytometry of in vivo assays. Cells from the RF and BM of transplanted mice
were stained in 96-well U-bottom plates (Corning, 351177) for 45 min at 4 °C. The
following antibodies were used (all from BD Biosciences, unless stated otherwise):
CD45 APC-Cy7 (1:100, 348795560566), CD45 A700 (1:100, 560566), CD33 APC
(1:100, 340474), and CD19 V450 (1:100, 560353), CD41 PE-Cy5 (1:200, Beckman
Coulter, 6607116), GlyA PE (1:100, Beckman Coulter, IM2211U), and CD3 FITC
(1:100, 349201). For NSGW41 mice at 12 weeks, CD3 FITC staining was omitted.
Cells were analyzed on the FACSCelesta (BD Biosciences).
CRISPR/Cas9 efficiency in cells and engrafted mice. After each CRISPR/Cas9
RNP electroporation, a small subset of cells was cultured in X-VIVO 10 media (as
described above) for 5–7 days in order to validate CRISPR/Cas9 efficiency.
Genomic DNA was isolated from bulk cells and the CRISPR/Cas9 engineered
genomic locus was amplified via PCR as described above. Sanger sequencing was
carried out using the reverse PCR primer and the chromatograms were analyzed
using the online tool TIDE (https://tide.deskgen.com/)60 in order to verify CRISPR/
Cas9 editing in control, GATA1-Short and GATA1-Long edited bulk cells. Because
of the large deletion size of control (200 bp) and GATA1-Short (400 bp) edited
cells, the CRISPR/Cas9 efficiency was evaluated based on the percentage of aber-
rant sequences after the gRNA cut site (Supplementary Fig. 7e).
For each transplanted mouse, CRISPR/Cas9 efficiency of control and GATA1-
Short edited cells was evaluated in the RF using the same approach. Only mice that
showed a CRISPR/Cas9 knockout efficiency of >90% as determined by the
percentage of aberrant sequences after the gRNA cut site and a CD45+ engraftment
level in the RF of >5% were utilized in the analysis. Because only one X-
chromosome needed to be edited for GATA1-Short, single clonal engraftment was
visible based on individual chromatograms (Supplementary Fig. 7f). GATA1-Short
edited LT-HSCs transplanted mice with more than one clone were included into
our near-clonal xenotransplantation analysis, as long as the CRISPR/Cas9
knockout efficiency of >90% and engraftment criteria of >5% were satisfied.
Methylcellulose colony formation assay. Totally, 1 × 105 cells from the RF of
xenotransplanted mice were transferred to 1 ml of MethoCult H4034 Optimum
methylcellulose medium (StemCell Technologies, 04034) and plated onto a 35 mm
dish for human-specific colony formation. After 10–11 days, individual colonies
were collected, washed in PBS and genomic DNA was isolated as described above.
Individual CRISPR/Cas9 edits were determined using PCR amplification and
Sanger sequencing with the reverse PCR primer as described above.
Cellular morphology. The RF and BM of genetically verified control and GATA1-
Short edited LT-HSCs injected NSGW41 mice were thawed and five samples per
condition were pooled together. Murine cells were depleted from each pooled
sample using the Mouse Depletion Kit (Miltenyi Biotec). Cells were stained for 30
min at 4 °C with the following antibodies: CD45 V500 (1:100, 560777, HI30), GlyA
PE (1:100, Beckman Coulter, IM2211U), and CD41 PE-Cy5 (1:200, Beckman
Coulter, 6607116, P2). GlyA+CD45− sorted cells from RF were washed in PBS with
2.5% FBS and then cytospinned using the CytoSpin 4 instrument (112×g for 10
min, high acceleration, ThermoFisher) according to manufacturer’s instructions.
CD41+ sorted cells from BM were cytospinned at 55×g for 10 min with medium
acceleration.
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CRISPR/Cas9 off-target analysis. Genomic loci that were similar to the gRNA
target sequence were identified with Cas0-OFFinder (http://www.rgenome.net/cas-
offinder)61, using a mismatch number of 2–4 and a DNA/RNA bulge size of 0. Two
genomic loci with 2 mismatches and 10 genomic loci with 3 mismatches were chosen
for GATA1-Short gRNA-1, 8 genomic loci with 3 mismatches and 1 genomic loci
with 4 mismatches for GATA1-Short gRNA-2, 4 genomic loci with 3 mismatches and
7 genomic loci with 4 mismatches for GATA1-Long gRNA-1, 3 genomic loci with 2
mismatches, 2 genomic loci with 3 mismatches and 6 genomic loci with 4 mismatches
for Control gRNA-1, and 1 genomic loci with 3 mismatches and 11 genomic loci with
4 mismatches for Control gRNA-2. PCR primers were designed to amplify 500 bp
around these genomic loci. 20–30 single cell colonies that were positively identified
with the correct CRISPR/Cas9 edit were selected from each cell type and genotyped
for PCR amplification. PCR products were column purified and subsequent Sanger
sequencing with both the forward and reverse PCR primer was carried out. TIDE
analysis was used to assess any CRISPR/Cas9 cleavage efficiency.
PCR primers:
FW_GATA1Short_gRNA1_chr4_118059061: 5′-
CCCTCAAACTTCCCGACTAAGG-3′
RV_GATA1Short_gRNA1_chr4_118059061: 5′-
GCTCAGATGTGACTGGGCG-3′
FW_GATA1Short_gRNA1_chr16_35544187: 5′-
CGCAGGTTTAGCAAAGTTCCC-3′
RV_GATA1Short_gRNA1_chr16_35544187: 5′-
CCAGATGGGTTTCTGCTTTTACGA-3′
FW_GATA1Short_gRNA1_chr22_44756609: 5′-
GGGTTTTTCTGGGCTGCAAG-3′
RV_GATA1Short_gRNA1_chr22_44756609: 5′-
ACATAATAGTATTGCAGTAATGCGG-3′
FW_GATA1Short_gRNA1_chr19_32673314: 5′-
CTCTAGGGCCGCTTCTCAGT-3′
RV_GATA1Short_gRNA1_chr19_32673314: 5′-
ACGCTACATAGGGTCGTTCC-3′
FW_GATA1Short_gRNA1_chr15_52109094: 5′-
GTTTGGACTGGTCGAGCCT-3′
RV_GATA1Short_gRNA1_chr15_52109094: 5′-
GAGTGCGAACCTCTCATCTCTC-3′
FW_GATA1Short_gRNA1_chr10_53712490: 5′-
CCAGTCAAGCACCTAGCGTA-3′
RV_GATA1Short_gRNA1_chr10_53712490: 5′-
GACTAGAAAGGCCTGAACCTCT-3′
FW_GATA1Short_gRNA1_chr14_72742463: 5′-
GGTCCCTTCCAGCACGTAAT-3′
RV_GATA1Short_gRNA1_chr14_72742463: 5′-
CCTCCCAATCCGGGAACAAC-3′
FW_GATA1Short_gRNA1_chr16_71816748: 5′-
TCTGGGGTACTAGAGGGGAAC-3′
RV_GATA1Short_gRNA1_chr16_71816748: 5′-
TCAGGCCAGCATACATCGTG-3′
FW_GATA1Short_gRNA1_chr1_223704955: 5′-
CTGAAATGTCGGCCCTGCAA-3′
RV_GATA1Short_gRNA1_chr1_223704955: 5′-
CCGAGGATGTAGTCATGGTGG-3′
FW_GATA1Short_gRNA1_chr17_80332977: 5′-
CCTTGGGTCTGCGTGAAGAT-3′
RV_GATA1Short_gRNA1_chr17_80332977: 5′-
AGTCACCTCTTAACTCTAACAGAAA-3′
FW_GATA1Short_gRNA1_chr10_20221643: 5′-
AGTGCAGTTAGAACAGACCAGC-3′
RV_GATA1Short_gRNA1_chr10_20221643: 5′-
GACAGACCTGTCAATCTGCTTTAT-3′
FW_GATA1Short_gRNA1_chr18_8376641: 5′-
GAGGACTGGCTGTTTCATCG-3′
RV_GATA1Short_gRNA1_chr18_8376641: 5′-
CACTATTCTCAGGAGCGGTCT-3′
FW_GATA1Short_gRNA2_chr5_178537945: 5′-
CATGACAGGCGCCTTCTTTACT-3′
RV_GATA1Short_gRNA2_chr5_178537945: 5′-
GAACATCTCCCCTTCAGCTCCT-3′
FW_GATA1Short_gRNA2_chr13_113094529: 5′-
TAGGTGTTGAACATGACCGTGG-3′
RV_GATA1Short_gRNA2_chr13_113094529: 5′-
ACAAAGTGCTGCTGAGACAGAG-3′
FW_GATA1Short_gRNA2_chr21_42868084: 5′-
AGCACACAACCTTCAAAAGACG-3′
RV_GATA1Short_gRNA2_chr21_42868084: 5′-
GTGGGTGGAATGTCACCTTACT-3′
FW_GATA1Short_gRNA2_chr10_123397080: 5′-
AATGCTGAGAGGCTTCCATTCC-3′
RV_GATA1Short_gRNA2_chr10_123397080: 5′-
CAAGATGTGCCTCCTCTCTGTG-3′
FW_GATA1Short_gRNA2_chr8_35663175: 5′-
TCACAAGTTTGTTAGAGCGGTG-3′
RV_GATA1Short_gRNA2_chr8_35663175: 5′-
TGCTCTCAGCAGTAGATCTGG-3′
FW_GATA1Short_gRNA2_chr8_107174119: 5′-
CTCAGCGAGGCACAGAATTG-3′
RV_GATA1Short_gRNA2_chr8_107174119: 5′-
AGCGGCTACCCCATAATAGC-3′
FW_GATA1Short_gRNA2_chr12_2085541: 5′-
TTAAGGCAATGTCAACCTTTTCCA-3′
RV_GATA1Short_gRNA2_chr12_2085541: 5′-
AGACGATGCAGGACCACCTA-3′
FW_GATA1Short_gRNA2_chr3_127784219: 5′-
TAACCCCCTTTGGGAGCACA-3′
RV_GATA1Short_gRNA2_chr3_127784219: 5′-
GCAGTGGGACGGCTATATCT-3′
FW_GATA1Short_gRNA2_chr7_17679912: 5′-
AGTATGCACATCCAGTTGGGG-3′
RV_GATA1Short_gRNA2_chr7_17679912: 5′-
CTGCTTGCACTGCTTAACGA-3′
FW_GATA1Long_gRNA_chr8_109403836: 5′-
CCCAAATATCAGTTCCATTGGGC-3′
RV_GATA1Long_gRNA_chr8_109403836: 5′-
GCAGCTGTTAACAAGAGAGTGC-3′
FW_GATA1Long_gRNA_chr3_77895170: 5′-
TTCCTCGCATCACATACGCC-3′
RV_GATA1Long_gRNA_chr3_77895170: 5′-
ACCAGATTTCAGCCACTTGGA-3′
FW_GATA1Long_gRNA_chr4_22175316: 5′-
AGCGCTTGAATACCTTCAGCAT-3′
RV_GATA1Long_gRNA_chr4_22175316: 5′-
GGAGGTGGCACAAGGTAGGTA-3′
FW_GATA1Long_gRNA_chr13_51458879: 5′-
AGAATGGTGACCCTGGCTTA-3′
RV_GATA1Long_gRNA_chr13_51458879: 5′-ATTGGCTGGACAGTTTCGC-3′
FW_GATA1Long_gRNA_chr15_62326516: 5′-
TAGGCGGGAATGTCAAAGCC-3′
RV_GATA1Long_gRNA_chr15_62326516: 5′-
GAGCTGGGACCCACGATAAAA-3′
FW_GATA1Long_gRNA_chr8_81290900: 5′-
AACGGGCACTTTAACAGGGAA-3′
RV_GATA1Long_gRNA_chr8_81290900: 5′-
AACCTTTGTCAGACCAACTCTGT-3′
FW_GATA1Long_gRNA_chr7_40859472: 5′-
AAGCTCGTTTGCTGCTTTACTG-3′
RV_GATA1Long_gRNA_chr7_40859472: 5′-
CTCCGCTCTTATGCTCTCTAGC-3′
FW_GATA1Long_gRNA_chr12_20017977: 5′-
ATTAGGTCAGTCCAAGCCAACA-3′
RV_GATA1Long_gRNA_chr12_20017977: 5′-
TCTCCCTCTTATCAATACCCCCAAC-3′
FW_GATA1Long_gRNA_chr12_94844478: 5′-
TTGCTAGATACAGTCCTTGCCTG-3′
RV_GATA1Long_gRNA_chr12_94844478: 5′-
CCATTGTCTTGCAGATGTTCTCA-3′
FW_GATA1Long_gRNA_chr2_15662510: 5′-
ACCGACATGGGCCTAAGGATA-3′
RV_GATA1Long_gRNA_chr2_15662510: 5′-
GGCAGCTTGTCTTGAGAATGG-3′
FW_GATA1Long_gRNA_chr9_76619884: 5′-
ATCCCTCTCAAGCAGCCTAAT-3′
RV_GATA1Long_gRNA_chr9_76619884: 5′-
ATTTGCTCACAGAGAAATCACACCA-3′
FW_Control_gRNA1_chr7_3081168: 5′-
AAATTATCCACATTAATCGGGAAGCC-3′
RV_Control_gRNA1_chr7_3081168: 5′-
TTGTTTCAAAATATCACCGTTGGCA-3′
FW_Control_gRNA1_chr7_135691300: 5′-
CTTTGAGTCTTTCCTCCCATGC-3′
RV_Control_gRNA1_chr7_135691300: 5′-
ACTGGGGGTAGCTCTAGTTGAA-3′
FW_Control_gRNA1_chr3_55088990: 5′-CTGTGTCACTTGGCTCGTCT-3′
RV_Control_gRNA1_chr3_55088990: 5′-CATGTAGTGAGTACCGGGGC-3′
FW_Control_gRNA1_chr5_4882788: 5′-
AGCAGCCAACTTGGAAACATAAG-3′
RV_Control_gRNA1_chr5_4882788: 5′-AATCAGGCCTCAGAACCATCTT-3′
FW_Control_gRNA1_chr16_48579049: 5′-
TTACCACACTCCACTCCTCTGT-3′
RV_Control_gRNA1_chr16_48579049: 5′-
CCTGTGTTCCTGAACCTCCTAAT-3′
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FW_Control_gRNA1_chr1_191051674: 5′-
ATCCAAGCATACATGACAGAGAT-3′
RV_Control_gRNA1_chr1_191051674: 5′-
GTATCTTGTGGGCACAACCTTT-3′
FW_Control_gRNA1_chr12_114950867: 5′-
CAATCCTGCCACATTTCTGCATAC-3′
RV_Control_gRNA1_chr12_114950867: 5′-
CTTGCCTGTCTCTCAAAGCATC-3′
FW_Control_gRNA1_chr21_34622361: 5′-
AGGATTTCAGCTCTAGCAACCA-3′
RV_Control_gRNA1_chr21_34622361: 5′-
CCCCATTTTAGACTTATGCCCCC-3′
FW_Control_gRNA1_chr2_30448683: 5′-
CGTAATAGCGCTTGTGTTTCAGT-3′
RV_Control_gRNA1_chr2_30448683: 5′-GCTAGATGACTGAGTTGGCAC-3′
FW_Control_gRNA1_chr6_169886852: 5′-
AACAGATGATTCTGCAGGCAAAC-3′
RV_Control_gRNA1_chr6_169886852: 5′-
GACGATCTTTTAGCTGTCCCCA-3′
FW_Control_gRNA1_chr20_52425093: 5′-
CAACCTGTACTCTGGGACGTAG-3′
RV_Control_gRNA1_chr20_52425093: 5′-
CGTGGAAACTTCTTCCTTGTCG-3′
FW_Control_gRNA2_chr4_1100146: 5′-TGTAAAGGCGTGCTGTTGGT-3′
RV_Control_gRNA2_chr4_1100146: 5′-ATCTGACGGTGTTGTGACTGG-3′
FW_Control_gRNA2_chr16_85653916: 5′-GTGTGTGTGAAGGCCGGTA-3′
RV_Control_gRNA2_chr16_85653916: 5′-CTCCACAATGAGGCGTTCCC-3′
FW_Control_gRNA2_chr2_118858930: 5′-CAGGAGACGCTCCAAGTCG-3′
RV_Control_gRNA2_chr2_118858930: 5′-TCCCTCACGTACCAGTCGG-3′
FW_Control_gRNA2_chr21_42232307: 5′-ATGGACCAACTCTCACAGCA-3′
RV_Control_gRNA2_chr21_42232307: 5′-GGCCTCCATTTGAGAACGTG-3′
FW_Control_gRNA2_chr12_12496109: 5′-
TGTGGCGTGTAGGTAAAGAGAC-3′
RV_Control_gRNA2_chr12_12496109: 5′-
TGTATCTGAGGTGAACCACTGC-3′
FW_Control_gRNA2_chr19_18226209: 5′-
GACACCCAGAGTTCATTGTGAG-3′
RV_Control_gRNA2_chr19_18226209: 5′-
GCTTTTGGTGAATCAGAGCATCC-3′
FW_Control_gRNA2_chr14_96046026: 5′-
CATGGTGTGGACTGTTTCTGTT-3′
RV_Control_gRNA2_chr14_96046026: 5′-
AGGTTTTGCCAAGCTCTACACA-3′
FW_Control_gRNA2_chr5_2514714: 5′-CACAGGGTTTGGTGTTTGTAGG-3′
RV_Control_gRNA2_chr5_2514714: 5′-TGATCTGGCTTGACTTGCTTCC-3′
FW_Control_gRNA2_chr8_10811909: 5′-
AGGAAGACAAATCCTAAGACAGCC-3′
RV_Control_gRNA2_chr8_10811909: 5′-
AAGTTTTACGTTTTCCTCGACCAC-3′
FW_Control_gRNA2_chr3_122079794: 5′-
AGATAAGCCAAGCCAGATTCTTCA-3′
RV_Control_gRNA2_chr3_122079794: 5′-
CTGCTTGGAATTCCCACATTACTC-3′
FW_Control_gRNA2_chr7_2644811: 5′-
GTTTATAGACAACCCACTGAGCAC-3′
RV_Control_gRNA2_chr7_2644811: 5′-
CTCATTGGCACTACTGCAGAGAAA-3′
FW_Control_gRNA2_chr15_54082949: 5′-
ACTCATCTTAAGGAACCGTCGC-3′
RV_Control_gRNA2_chr15_54082949: 5′-
CATAGCCACATCCAAAGGTCCA-3′
Karyotyping analysis. Lineage depleted cord blood cells were thawed and CD34+
CD38− cells were sorted using CD34 APC-Cy7 (clone 581, custom conjugation) and
CD38 PE-Cy7 (335825, HB7). Cells were pre-cultured for 36–48 h in serum-free
media and subsequently electroporated as described above. After overnight incuba-
tion, media was changed to IMDM (Thermo Fisher, 12440061) with 10% FBS (Sigma,
15A085), 1× L-Glutamine (Thermo Fisher, 25030081), 1× Penicillin–Streptomycin
(Thermo Fisher, 15140122) and the following cytokines (all from Miltenyi Biotec):
FLT3L (100 ng/mL), G-CSF (10 ng/mL), SCF (100 ng/mL), TPO (15 ng/mL), and IL-6
(10 ng/mL) to allow for cell expansion. Subsequently, karyotyping of chromosomes
was performed according to standard procedures. Metaphase slides were prepared,
then banded with trypsin and stained with Leishman’s stain. The G-banded slides
were scanned and metaphases captured using an automated imaging system (Meta-
Systems). Metaphases were analyzed using Ikaros image analysis software (Meta-
Systems). For each condition, 20 metaphases were analyzed by G-banded karyotyping
for numerical and structural abnormalities.
Statistical analysis. Error bars represent standard deviations. Statistical sig-
nificance was assessed using two-tailed unpaired student’s t test.
Life sciences reporting summary. Additional information on experimental design
is available in the Nature Research Reporting Summary linked to this article.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All datasets generated in this study are available within the paper or from the
corresponding author upon reasonable request. Full length gel pictures and western assay
can be found in Supplementary Fig. 12.
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